An exploratory study to investigate the effect of FE 999302 when given during different time periods to women undergoing controlled ovarian stimulation with follitropin delta

2023-508149-42-00 Protocol 000427 Human pharmacology (Phase I) - Other Ended

Start 16 Jul 2024 · End 5 Sep 2025 · Status Ended · 5 EU/EEA countries · 15 sites · Protocol 000427

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 201
Countries 5
Sites 15

Infertility in women undergoing assisted reproductive technologies (ART)

Key facts

Sponsor
Ferring Pharmaceuticals A/S
Participant type
Patients
Age range
18-64 years
Gender
Female
Therapeutic area
Diseases [C] - Female Urogenital Diseases and Pregnancy Complications [C13]
Trial duration
16 Jul 2024 → 5 Sep 2025
Decision date (initial)
2024-06-19
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-508149-42-00
WHO UTN
U1111-1297-6494

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Infertility in women undergoing assisted reproductive technologies (ART)

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Ferring Pharmaceuticals A/S

Sponsor organisation
Ferring Pharmaceuticals A/S
Address
Amager Strandvej 405
City
Kastrup
Postcode
2770
Country
Denmark

Scientific contact point

Organisation
Ferring Pharmaceuticals A/S
Contact name
Sarah Grover

Public contact point

Organisation
Ferring Pharmaceuticals A/S
Contact name
Clinical and Translational Sciences

Locations

5 EU/EEA countries · 15 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ended 27 2
Czechia Ended 40 3
Denmark Ended 27 2
Norway Ended 39 3
Spain Ended 68 5
Rest of world 0

Investigational sites

Belgium

2 sites · Ended
Antwerp University Hospital
Center for Reproductive Medicine, Drie Eikenstraat 655, 2650, Edegem
UZ Brussel
Center for Reproductive Medicine, Laarbeeklaan 101, 1090, Jette

Czechia

3 sites · Ended
FertiCare SE
-, Radlicka 3185/1c, Smichov, Prague
Ivf Cube SE
Clinic for Assisted Reproduction, Evropska 423/178, 160 00, Prague
Gynem s.r.o.
Gynem Fertility Clinic, Na Orechovce 576/7, Stresovice, Prague

Denmark

2 sites · Ended
Hvidovre Hospital
The Fertility Clinic, Kettegaard Alle 30, 2650, Hvidovre
Rigshospitalet
Fertility Department, Blegdamsvej 9, 2100, Copenhagen Oe

Norway

3 sites · Ended
Medicus Bergen AS
-, Bredalsmarken 15, 5006, Bergen
Medicus Trondheim AS
Gynecology, Reproductive Medicine and Clinical Trials, Beddingen 8, 7042, Trondheim
Sykehuset Telemark Hf
Fertilitetsavdelingen Sør, Aalsgate 41, 3913, Porsgrunn

Spain

5 sites · Ended
Hospital Universitari Dexeus Grupo Quironsalud
Department of Gynecology and Obstetrics, Calle De Sabino Arana 5-19, 08028, Barcelona
Ivi Sevilla S.L.
Reproductive Medicine, Calle Americo Vespucio 19, Parque Cientifico Y Tecnologico Cartuja 93, Sevilla
Ivi Valencia S.L.
Reproductive Medicine, Placa Policia Local 3, 46015, Valencia
Ivi Madrid S.L.
Reproductive Medicine, Avenida Talgo 68-70, 28023, Madrid
Ginefiv S.L.
Obstetrics and gynaecology, Calle De Zurbano 51, 28010, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2024-10-15
Czechia 2024-07-29 2024-08-12
Denmark 2024-09-26 2024-10-17
Norway 2024-11-14 2024-12-09
Spain 2024-07-16 2024-07-17

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-26 Denmark Acceptable with conditions
2024-06-17
2024-06-17
2 SUBSTANTIAL MODIFICATION SM-1 2024-07-10 Denmark Acceptable
2024-08-27
2024-09-02
3 NON SUBSTANTIAL MODIFICATION NSM-1 2024-10-14 Acceptable
2024-08-27
2024-10-14
4 SUBSTANTIAL MODIFICATION SM-2 2025-01-29 Denmark Acceptable
2025-04-25
2025-04-25
5 NON SUBSTANTIAL MODIFICATION NSM-3 2025-07-04 Acceptable
2025-04-25
2025-07-04